These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32960984)

  • 1. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
    Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
    J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
    Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review.
    Bierhoff M; Smolders EJ; Tarning J; Burger DM; Spijker R; Rijken MJ; Angkurawaranon C; McGready R; White NJ; Nosten F; van Vugt M
    Antivir Ther; 2019; 24(7):529-540. PubMed ID: 31868655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of tenofovir during pregnancy and postpartum.
    Best BM; Burchett S; Li H; Stek A; Hu C; Wang J; Hawkins E; Byroads M; Watts DH; Smith E; Fletcher CV; Capparelli EV; Mirochnick M;
    HIV Med; 2015 Sep; 16(8):502-11. PubMed ID: 25959631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
    Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
    Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection.
    Celen MK; Mert D; Ay M; Dal T; Kaya S; Yildirim N; Gulsun S; Barcin T; Kalkanli S; Dal MS; Ayaz C
    World J Gastroenterol; 2013 Dec; 19(48):9377-82. PubMed ID: 24409065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
    Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
    J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
    Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
    Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of hepatitis B surface antigen in pregnant women with and without tenofovir disoproxil fumarate.
    Chang HL; Wen WH; Lee CN; Chiu YE; Liu CJ; Chang MH; Lin LH; Chen HL
    J Viral Hepat; 2022 Feb; 29(2):107-114. PubMed ID: 34724288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
    Van Rompay KK; Durand-Gasselin L; Brignolo LL; Ray AS; Abel K; Cihlar T; Spinner A; Jerome C; Moore J; Kearney BP; Marthas ML; Reiser H; Bischofberger N
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3144-60. PubMed ID: 18573931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes.
    Chen HL; Lee CN; Chang CH; Lai MW; Tsai MC; Mu SC; Liu CJ; Shih JC; Wen WH; Hu RT; Huang CP; Hu KC; Chen CP; Lee CL; Chien RN; Chang KC; Hsu HY; Lee CC; Ni YH; Chang MH
    Liver Int; 2024 Jun; 44(6):1422-1434. PubMed ID: 38456620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
    Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.
    Cressey TR; Harrison L; Achalapong J; Kanjanavikai P; Patamasingh Na Ayudhaya O; Liampongsabuddhi P; Siriwachirachai T; Putiyanun C; Suriyachai P; Tierney C; Salvadori N; Chinwong D; Decker L; Tawon Y; Murphy TV; Ngo-Giang-Huong N; Siberry GK; Jourdain G;
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
    Benaboud S; Hirt D; Launay O; Pannier E; Firtion G; Rey E; Bouazza N; Foissac F; Chappuy H; Urien S; Tréluyer JM
    Antimicrob Agents Chemother; 2012 Feb; 56(2):857-62. PubMed ID: 22123690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
    Kayes T; Crane H; Symonds A; Dumond J; Cottrell M; Di Girolamo J; Manandhar S; Lim TH; Gane E; Kashuba A; Levy MT
    Aliment Pharmacol Ther; 2022 Aug; 56(3):510-518. PubMed ID: 35599363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
    AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate.
    Li S; Jin J; Jiang Y; Shi J; Jiang X; Lin N; Ma Z
    Int J Antimicrob Agents; 2023 Mar; 61(3):106726. PubMed ID: 36646229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.
    Eke AC; Shoji K; Best BM; Momper JD; Stek AM; Cressey TR; Mirochnick M; Capparelli EV
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
    Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
    Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.